Annovis Bio, Inc. (ANVS)

NYSE: ANVS · Real-Time Price · USD

1.510

+0.040 (2.72%)

Apr 23, 2025, 4:00 PM EDT - Market closed

Annovis Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	-24.59	-56.2	-25.33	-14.49	-5.46	Upgrade
Other Amortization	-	-	-	-	0	Upgrade
Stock-Based Compensation	3.84	4.63	9.15	4.7	1.86	Upgrade
Other Operating Activities	-1.82	11.84	-	-	0.03	Upgrade
Change in Accounts Payable	1.01	-2.67	3.27	0.35	-0.7	Upgrade
Change in Other Net Operating Assets	-0.33	2.44	-4.41	0.31	0.29	Upgrade
Operating Cash Flow	-21.89	-39.97	-17.31	-9.13	-3.97	Upgrade
Issuance of Common Stock	26.69	17.34	0	46.74	12.04	Upgrade
Financing Cash Flow	26.69	17.34	0	46.74	12.04	Upgrade
Net Cash Flow	4.8	-22.62	-17.31	37.61	8.07	Upgrade
Levered Free Cash Flow	-12.17	-23.75	-7.93	-3.73	-3.02	Upgrade
Unlevered Free Cash Flow	-12.17	-23.75	-7.93	-3.73	-3.02	Upgrade
Change in Net Working Capital	-0.68	0.23	1.14	-0.66	0.73	Upgrade

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q